First results of [C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 418-423

  Winter, Alexander ^a   Uphoff, Jens ^a   Henke, Rolf Peter ^b   Wawroschek, Friedhelm ^a  

^a KLINIKUM OLDENBURG   (Germany)

^b Institut Oldenburg   (Germany)

Author keywords

11C choline PET CT; Lymph node recurrence; Prostate cancer; Prostate specific antigen relapse; Secondary lymph node surgery

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; FEASIBILITY STUDY; GERMANY; IMMUNOLOGY; LYMPH NODE; METASTASIS; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; RADIOGRAPHY; REOPERATION; SCINTISCANNING; TIME; TREATMENT OUTCOME;

AGED; CARBON RADIOISOTOPES; CHOLINE; FEASIBILITY STUDIES; GERMANY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REOPERATION; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77953203770     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296298     Document Type: Article

References (26)

1. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-1368.
2. Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, Fazio F: Diagnosis of local recurrence after radical prostatectomy. BJU Int 2004; 93: 680-688.
3. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO: The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a metaanalysis. Clin Radiol 2008; 63: 387-395.
4. Tiguert R, Gheiler EL, Tefilli MV, Oskanian P, Banerjee M, Grignon DJ, Sakr W, Pontes JE, Wood DP Jr: Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999; 53: 367-371.
5. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ: Preoperative staging of pelvic lymph nodes in prostate cancer by 11 C-choline PET. J Nucl Med 2003; 44: 331-335.
6. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei DV, De Cobelli F, Del Maschio A, Rocco F, Rigatti P, Fazio F: Value of [ 11 C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [ 18 F]fluorodeox yglucose-positron emission tomography. J Urol 2003; 169: 1337-1340.
7. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ: 11 C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44: 32-38; discussion 38-39.
8. Hara T, Kosaka N, Kishi H: PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39: 990-995.
9. Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B: Intraindividual comparison of [ 11 C]acetate and [ 11 C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 25-30.
10. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, Da Pozzo L, Bocciardi A, Rigatti P, Fazio F: Detection of lymph-node metastases with integrated [ 11 C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423-429.
11. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A: Histological verification of 11 Ccholine- positron emission/computed tomography- positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008; 102: 446-451.
12. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Moller P, Wiegel T, Kuefer R, Gschwend JE: Evaluation of [ 11 C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100: 786-793.
13. Hacker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, Langsteger W, Janetschek G: Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [ 18 F]fluorocholine positron emission tomography- computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006; 176: 2014-2018; discussion 2018-2019.
14. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, Cservenyak T, Hany TF: Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 253-263.
15. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ: Visualization of prostate cancer with 11 C-choline positron emission tomography. Eur Urol 2002; 42: 18-23. (Pubitemid 35345101)
16. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ: 11 C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549-555.
17. Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, Severens JL, Adang EM, van der Kaa CH, Futterer JJ, Barentsz J: Mri with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008; 9: 850-856.
18. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499. (Pubitemid 36706536)
19. Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W: Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA ! 5 ng/ml? Mol Imaging Biol 2006; 8: 43-48.
20. Bader P, Burkhard FC, Markwalder R, Studer UE: Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 514-518; discussion 518.
21. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R: Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 2001; 166: 1715-1719.
22. Kitzbichler G, Rotter R, Höltl L, Zimmermann R: Detektion einer singulären Metastase eines Prostatakarzinoms nach RPE mittels PET-CT und PSA-Normalisierung nach Resektion. J Urol Urogynäkol 2008; 15(Sonderheft 2):31.
23. Catalona WJ, Miller DR, Kavoussi LR: Intermediate- term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 1988; 140: 540-543.
24. Bader P, Burkhard FC, Markwalder R, Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy: is there a chance of cure? J Urol 2003; 169: 849-854.
25. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004; 172: 2252-2255.
26. Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R: Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ! or = 10 ng/ml and biopsy Gleason score of ! or = 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006; 97: 1173-1178.